Harbour BioMed has officially entered into a strategic partnership with Bristol Myers Squibb (BMS) to jointly develop advanced therapeutic antibodies. This collaboration focuses on harnessing modern biotechnological power to address unmet medical needs in immunology and oncology.
financial details and collaboration structure Under the agreed terms, Harbour BioMed is set to receive an upfront payment of $90 million.
- Development milestones: The total potential value of the deal could reach $1.035 billion, including payments linked to research progress and commercialization milestones.
- Royalties: Harbour will also be entitled to tiered royalties based on sales if the programs under the collaboration gain regulatory approval.
core technological platform The partnership centers on the integration of the “Harbour Mice” platform—a technology that facilitates the generation of fully human antibodies with high specificity and therapeutic efficacy. Merging this capability with BMS’s extensive experience in drug discovery and development will optimize the potential of new biologics.
leveraging the chinese market advantage A notable aspect of the agreement is the opportunity to utilize Harbour’s established development infrastructure to accelerate programs by conducting early clinical trials in China. This strategy aims to shorten the roadmap for delivering transformative therapies to patients worldwide.
Prior to this alliance with BMS, Harbour had already made significant strides through a collaboration with Otsuka Pharmaceuticals in July to develop antibody-based treatments for autoimmunity, further solidifying its position in the international biotech landscape.
Source: https://www.bioxconomy.com/partnering/harbour-inks-90m-antibody-deal-with-bristol-myers-squibb